Difference between revisions of "CNS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(10 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
− | To volunteer, please [Contact us] with your page of interest. | + | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> |
− | + | {| class="wikitable" style="margin:auto" | |
− | ==WHO Classification of Tumours of the Central Nervous System (5th Edition) Content | + | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> |
− | |||
|- | |- | ||
− | !'''Disease'''!!'''Page Type'''!! | + | !'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author''' |
!'''Date Assigned to Author''' | !'''Date Assigned to Author''' | ||
!'''Target Completion Date''' | !'''Target Completion Date''' | ||
Line 18: | Line 17: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | | | + | |CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | ||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
Line 29: | Line 48: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Oligodendroglioma, IDH- | + | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] |
+ | |Disease | ||
+ | |Riley Lochner (trainee), Shashi Shetty (mentor) | ||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
Line 38: | Line 59: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Glioblastoma, IDH- | + | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] |
+ | |Disease | ||
+ | |Meenakshi Mehrotra | ||
| | | | ||
| | | | ||
Line 45: | Line 68: | ||
|LS | |LS | ||
| | | | ||
− | |Moved from " | + | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added |
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] |
+ | |Disease | ||
+ | |Scott Smith | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
Line 56: | Line 81: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
− | |Angiocentric | + | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 65: | Line 92: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 74: | Line 103: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 83: | Line 114: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan (Linda Cooley - previous version) | ||
| | | | ||
| | | | ||
Line 92: | Line 125: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] |
+ | |Disease | ||
+ | |Xiaolin (Lynn) Hu | ||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
Line 101: | Line 136: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] |
+ | |Disease | ||
+ | |Madina Sukhanova | ||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
Line 110: | Line 147: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Infant- | + | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 117: | Line 157: | ||
| | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Pilocytic | + | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] |
+ | |Disease | ||
+ | |Jeremy Pulvers | ||
|9/13/2022<br /> | |9/13/2022<br /> | ||
| | | | ||
Line 128: | Line 169: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |High- | + | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 137: | Line 180: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 146: | Line 191: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Subependymal | + | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 155: | Line 202: | ||
| | | | ||
|- | |- | ||
− | |Chordoid | + | |[[CNS5:Chordoid_glioma|Chordoid glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 164: | Line 213: | ||
| | | | ||
|- | |- | ||
− | |Astroblastoma, MN1- | + | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 173: | Line 224: | ||
| | | | ||
|- | |- | ||
− | |Ganglioglioma||Disease | + | |[[CNS5:Ganglioglioma|Ganglioglioma]] |
+ | |Disease | ||
+ | |Leila Moayed-Aloei | ||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
Line 182: | Line 235: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Gangliocytoma||Disease|| | + | |[[CNS5:Gangliocytoma|Gangliocytoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 191: | Line 257: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 200: | Line 268: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 209: | Line 279: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 218: | Line 290: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 227: | Line 301: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 236: | Line 312: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 245: | Line 323: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 254: | Line 334: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 263: | Line 345: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Central_neurocytoma|Central neurocytoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 272: | Line 367: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 281: | Line 378: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 290: | Line 389: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 299: | Line 400: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 308: | Line 411: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 317: | Line 422: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 326: | Line 433: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 335: | Line 444: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 344: | Line 455: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 353: | Line 466: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 362: | Line 477: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Subependymoma|Subependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 371: | Line 488: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 3 (CHOROID PLEXUS TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 389: | Line 519: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 398: | Line 530: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 407: | Line 541: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 4 (EMBRYONAL TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Medulloblastoma, WNT- | + | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] |
+ | |Disease | ||
+ | |Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | ||
|9/20/21 | |9/20/21 | ||
| | | | ||
Line 425: | Line 572: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Medulloblastoma, SHH- | + | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 434: | Line 616: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 443: | Line 627: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 452: | Line 638: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 461: | Line 682: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 5 (PINEAL TUMOURS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineocytoma|Pineocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 479: | Line 713: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 488: | Line 724: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineoblastoma|Pineoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 497: | Line 735: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 506: | Line 746: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 515: | Line 757: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Schwannoma|Schwannoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 533: | Line 788: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Neurofibroma|Neurofibroma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 542: | Line 799: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Perineurioma|Perineurioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 551: | Line 810: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 560: | Line 821: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 569: | Line 832: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 578: | Line 843: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 587: | Line 854: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 7 (MENINGIOMA) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Meningioma|Meningioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 605: | Line 885: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 623: | Line 916: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 632: | Line 927: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 641: | Line 938: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 650: | Line 949: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 659: | Line 960: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 668: | Line 971: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 677: | Line 982: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 686: | Line 993: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 695: | Line 1,004: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 704: | Line 1,015: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chordoma|Chordoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 713: | Line 1,026: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 9 (MELANOCYTIC TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 731: | Line 1,057: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 740: | Line 1,068: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Primary | + | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 758: | Line 1,099: | ||
| | | | ||
|- | |- | ||
− | |Immunodeficiency- | + | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 767: | Line 1,110: | ||
| | | | ||
|- | |- | ||
− | |Lymphomatoid | + | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 776: | Line 1,121: | ||
| | | | ||
|- | |- | ||
− | |Intravascular | + | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 785: | Line 1,132: | ||
| | | | ||
|- | |- | ||
− | |MALT | + | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 794: | Line 1,143: | ||
| | | | ||
|- | |- | ||
− | |Other | + | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 803: | Line 1,154: | ||
| | | | ||
|- | |- | ||
− | |Anaplastic | + | |[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 810: | Line 1,163: | ||
|MS | |MS | ||
| | | | ||
− | |2021 template added | + | |2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? |
+ | |- | ||
+ | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 821: | Line 1,220: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 830: | Line 1,231: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 11 (GERM CELL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 848: | Line 1,262: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 12 (TUMOURS OF THE SELLAR REGION |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 866: | Line 1,293: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 875: | Line 1,304: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 884: | Line 1,315: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 893: | Line 1,326: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 902: | Line 1,337: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 13 (METASTASES TO THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 920: | Line 1,368: | ||
| | | | ||
|- | |- | ||
− | |Metastases to the | + | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 929: | Line 1,379: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] |
+ | |Disease | ||
+ | |Ngoni Faya (trainee) + Madina Sukhanova | ||
| | | | ||
| | | | ||
Line 947: | Line 1,410: | ||
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 956: | Line 1,421: | ||
| | | | ||
|- | |- | ||
− | |Schwannomatosis||Disease | + | |[[CNS5:Schwannomatosis|Schwannomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 965: | Line 1,432: | ||
| | | | ||
|- | |- | ||
− | |Von Hippel-Lindau | + | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 974: | Line 1,443: | ||
| | | | ||
|- | |- | ||
− | |Tuberous | + | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 983: | Line 1,454: | ||
| | | | ||
|- | |- | ||
− | |Li-Fraumeni | + | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 992: | Line 1,465: | ||
| | | | ||
|- | |- | ||
− | |Cowden | + | |[[CNS5:Cowden_syndrome|Cowden syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,001: | Line 1,476: | ||
| | | | ||
|- | |- | ||
− | |Constitutional | + | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,010: | Line 1,487: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] |
+ | |Disease | ||
+ | |Jennifer Laffin | ||
|8/22/2023 | |8/22/2023 | ||
| | | | ||
Line 1,019: | Line 1,498: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Naevoid | + | |[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,028: | Line 1,509: | ||
| | | | ||
|- | |- | ||
− | |Rhabdoid | + | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,037: | Line 1,520: | ||
| | | | ||
|- | |- | ||
− | |Carney | + | |[[CNS5:Carney_complex|Carney complex]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,046: | Line 1,531: | ||
| | | | ||
|- | |- | ||
− | |DICER1 | + | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,055: | Line 1,542: | ||
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,064: | Line 1,553: | ||
| | | | ||
|- | |- | ||
− | |Melanoma- | + | |[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,073: | Line 1,564: | ||
| | | | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,082: | Line 1,575: | ||
| | | | ||
|- | |- | ||
− | |BAP1 | + | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,091: | Line 1,586: | ||
| | | | ||
|- | |- | ||
− | |Fanconi | + | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,100: | Line 1,597: | ||
| | | | ||
|- | |- | ||
− | |ELP1- | + | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,109: | Line 1,608: | ||
| | | | ||
|- | |- | ||
− | |} | + | |} |
Latest revision as of 14:00, 25 February 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.